{"prompt": "['the data. Data entered manually will be collected using EDC through use of eCRFs. Sites', 'will be responsible for data entry into the EDC system. In the event of discrepant data, the', 'CRO will request data clarification from the sites, which the sites will resolve electronically in', 'the EDC system.', 'The CRO will produce a Data Quality Plan that describes the quality checking to be', 'performed on the data. Central laboratory data and ePRO data will be sent directly to the', \"either the Sponsor or the vendor using the Sponsor's standard procedures to handle and\", 'process the electronic transfer of these data.', 'The Sponsor will perform oversight of the data management of this study, including approval', \"of the CRO's data management plans and specifications. Data will be periodically\", \"transferred electronically from the CRO to the Sponsor, and the Sponsor's standard\", 'procedures will be used to handle and process the electronic transfer of these data.', \"eCRFs and correction documentation will be maintained in the EDC system's audit trail.\", 'System backups for data stored at the CRO and records retention for the study data will be', \"consistent with the CRO's standard procedures.\", '7.2', 'ELECTRONIC CASE REPORT FORMS', 'eCRFs are to be completed through use of a Sponsor-designated EDC system. Sites will', 'receive training and have access to a manual for appropriate eCRF completion. eCRFs will', 'be submitted electronically to the Sponsor and should be handled in accordance with', 'instructions from the Sponsor.', 'All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed', 'and electronically signed and dated by the investigator or a designee.', 'At the end of the study, the investigator will receive patient data for his or her site in a', 'readable format on a compact disc that must be kept with the study records.', 'Acknowledgement of receipt of the compact disc is required.', '7.3', 'ELECTRONIC PATIENT-REPORTED OUTCOME DATA', 'PRO data will be collected electronically through the use of electronic devices provided by', 'an ePRO vendor (HRQoL and EQ-5D-5L) or using a paper questionnaire (EmiPref). Paper', 'versions of the questionnaires are also available in case of ePRO outage or if an ePRO device is', 'otherwise unavailable. The electronic device is designed for entry of data in a manner that is', 'attributable, secure, and accurate, in compliance with electronic records: 21 Code of Federal', 'Regulations, Part 11. The PRO data from the device will be transmitted electronically to the', 'eCRF in real time. Only identified and trained users may view the data, and their actions (if', 'any) will become part of the audit trail. The Sponsor will have view-only access to PRO data.', 'The Sponsor will receive all data (including requested meta-data) entered by the patients on', 'the ePRO devices and all relevant study documentation.', 'Once the study is complete, the ePRO data, audit trail, and trial and system documentation', 'will be archived. The investigator will receive patient data for the site in both human- and', 'machine-readable formats on an archival-quality compact disc that must be kept with the', 'study records as source data. Acknowledgement of receipt of the compact disc is required.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '147 / Protocol MO39129, Version 3']['In addition, the Sponsor will receive all patient data in a machine-readable format on a', 'compact disc.', '7.4', 'SOURCE DATA DOCUMENTATION', 'Study monitors will perform ongoing source data verification to confirm that critical protocol', 'data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate,', 'complete, and verifiable from source documents.', 'Source documents (paper or electronic) are those in which patient data are recorded and', 'documented for the first time. They include, but are not limited to, hospital records, clinical', 'and office charts, laboratory notes, memoranda, PROs, evaluation checklists, pharmacy', 'dispensing records, recorded data from automated instruments, copies of transcriptions that', 'are certified after verification as being accurate and complete, microfiche, photographic', 'negatives, microfilm or magnetic media, X-rays, patient files, and records kept at pharmacies,', 'laboratories, and medico-technical departments involved in a clinical trial.', 'Before study initiation, the types of source documents that are to be generated will be clearly', 'defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly', 'into the eCRFs (i.e., no prior written or electronic record of the data) and considered source', 'data.', 'Source documents that are required to verify the validity and completeness of data entered', 'into the eCRFs must not be obliterated or destroyed and must be retained per the policy for', 'retention of records described in Section 0.', 'To facilitate source data verification, the investigators and institutions must provide the', 'Sponsor direct access to applicable source documents and reports for trial-related', 'monitoring, Sponsor audits, and IRB/EC review. The study site must also allow inspection by', 'applicable health authorities.', '7.5', 'USE OF COMPUTERIZED SYSTEMS', \"When clinical observations are entered directly into a study site's computerized medical\", 'record system (i.e., in lieu of original hardcopy records), the electronic record can serve as', 'the source document if the system has been validated in accordance with health authority', 'requirements pertaining to computerized systems used in clinical research. An acceptable', 'computerized data collection system allows preservation of the original entry of data. If', 'original data are modified, the system should maintain a viewable audit trail that shows the', 'original data as well as the reason for the change, name of the person making the change,', 'and date of the change.', '7.6', 'RETENTION OF RECORDS', 'Records and documents pertaining to the conduct of this study and the distribution of IMP,', 'including eCRFs, ePRO data, Informed Consent Forms, laboratory test results, and', 'medication inventory records, must be retained by the Principal Investigator for at least', '15 years after completion or discontinuation of the study or for the length of time required by', 'relevant national or local health authorities, whichever is longer. After that period of time, the', 'documents may be destroyed, subject to local regulations.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '148 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}